Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2071 to 2085 of 9004 results

  1. Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy [ID6711]

    Awaiting development Reference number: GID-TA11944 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Transverse Tibial Transport

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Subcutaneous olanzapine for treating schizophrenia [TSID12289]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. CT guided fibrin glue sealing of CSF leak to treat spontaneous intracranial hypotension

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  5. NEMOST growing domino for Neuromuscular early onset scoliosis with Risser 0 in first surgical intention

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  6. Stereotactic anterior cingulotomy for intractable pain

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  7. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  8. Budesonide–glycopyrronium–formoterol fumarate for treating severe asthma in people 12 years and over TS ID 12018

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Mepolizumab for treating chronic obstructive pulmonary disease with eosinophil-associated exacerbations TSID12019

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Dupilumab for children with severe atopic dermatitis [TSID10434]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TSID10639]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Eszopiclone for treating insomnia [TSID12020]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]

    Awaiting development Reference number: GID-TA11792 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Fenebrutinib for treating relapsing multiple sclerosis [ID6577]

    Awaiting development Reference number: GID-TA11775 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]

    In development Reference number: GID-TA11553 Expected publication date: TBC

    Technology appraisal guidance
    In development